

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprox vet 100 mg tablets for dogs  
Carprofen

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Each tablet contains:

**Active substance:**

Carprofen 100 mg

**Excipients:**

Ferric oxide red (E172) 3.04 mg

Ferric oxide black (E172) 1.90 mg

**3. PHARMACEUTICAL FORM**

Tablet.

**4. PACKAGE SIZE**

20 tablets

50 tablets

100 tablets

500 tablets

**5. TARGET SPECIES**

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Oral use.

**8. WITHDRAWAL PERIOD**

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP:

Return any halved tablet to the opened blister and use within 24 hours.

**11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.

Keep the blister in the outer carton in order to protect from light and moisture.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Dispose of waste material in accordance with local requirements.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

KRKA, d.d., Novo mesto  
Šmarješka cesta 6  
8501 Novo mesto  
Slovenia

**16. MARKETING AUTHORISATION NUMBER**

Vm 01656/4013

**17. MANUFACTURER'S BATCH NUMBER**

Lot:

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BLISTERS**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprox vet 100 mg tablets for dogs  
Carprofen

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

KRKA

**3. EXPIRY DATE**

EXP:

**4. BATCH NUMBER**

Lot:

**5. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**PACKAGE LEAFLET FOR:**

**Carprox vet 100 mg tablets for dogs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

KRKA, d.d., Novo mesto  
Šmarješka cesta 6  
8501 Novo mesto  
Slovenia

Manufacturer responsible for batch release:

KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia  
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Carprox vet 100 mg tablets for dogs  
Carprofen

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each tablet contains:

Active substance:

Carprofen 100 mg

Excipients:

Ferric oxide red (E172) 3.04 mg  
Ferric oxide black (E172) 1.90 mg

Round, dark brown, marbled tablets with visible darker spots, one-side scored and bevel-edged.

The tablets can be divided into two equal parts.

**4. INDICATION(S)**

Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post operative pain.

## **5. CONTRAINDICATIONS**

Do not use in cats.

Do not use in pregnant or lactating bitches.

Do not use in dogs less than 4 months of age.

Do not use in case of hypersensitivity to active substance or to any of the excipients.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.

## **6. ADVERSE REACTIONS**

Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.

As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Dogs.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

For oral administration.

An initial dose of 2 to 4 mg carprofen per kg bodyweight per day is recommended to be given as a single or in two equally divided doses. Subject to clinical response, the dose may be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose.

Duration of treatment will be dependent upon the response seen, but the dog's condition should be re-appraised by the veterinary surgeon after 14 days therapy.

## **9. ADVICE ON CORRECT ADMINISTRATION**

To extend analgesic cover post-operatively, parenteral therapy with solution for injection may be followed with tablets at 4 mg/kg/day for up to 5 days.

## 10. WITHDRAWAL PERIOD

Not applicable.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Do not store above 25°C.

Keep the blister in the outer carton in order to protect from light and moisture.

Return any halved tablet to the opened blister and use within 24 hours.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister after "EXP". The expiry date refers to the last day of that month.

## 12. SPECIAL WARNING(S)

### Special precautions for use in animals:

Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.

### Use during pregnancy and lactation:

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.

### Interaction with other medicinal products and other forms of interaction:

Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of administration of the product. Carprofen is highly bound to plasma proteins and may compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

### Overdose (symptoms, emergency procedures, antidotes):

Although studies investigating the safety of carprofen at overdose have been performed, no signs of toxicity appeared when dogs were treated with carprofen at levels up to 6 mg/kg twice daily for 7 days (3 times the recommended dose rate of

4mg/kg) and 6mg/kg once daily for a further 7 days. (1.5 times the recommended dose rate of 4 mg/kg).

There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

**15. OTHER INFORMATION**

100 mg tablets are available in boxes of 20, 50, 100 and 500 tablets in blisters of 10 tablets.

Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

Approved 19 March 2020

A handwritten signature in black ink, appearing to read "Hunter.", is positioned below the approval date.